Pneumonia Therapeutics Market Report 2026

The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $11.46 billion in 2025 to $12.68 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing incidence of respiratory infections, rising hospitalization rates for pneumonia, widespread use of antibiotics, expansion of intensive care infrastructure, growing elderly population.

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $18.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing development of novel antibiotics and antivirals, rising adoption of rapid diagnostic testing, growing focus on antimicrobial resistance management, expansion of homecare pneumonia treatment models, increasing investment in vaccine-based prevention strategies. Major trends in the forecast period include increasing adoption of targeted antimicrobial therapies, rising use of combination drug regimens, growing focus on early pathogen identification, expansion of home-based oxygen therapy solutions, enhanced emphasis on hospital infection control protocols.

The increasing prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market going forward. Pneumonia is a lung infection that causes inflammation of the air sacs, often leading to symptoms such as coughing, fever, and difficulty breathing. The rise in pneumonia cases is linked to factors including aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections such as COVID-19 and influenza. Pneumonia therapeutics address the underlying causes of infection, including bacteria, viruses, or fungi, through targeted medications, while also supporting recovery with oxygen therapy, anti-inflammatory drugs, and symptom management. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based government agency, pneumonia affects approximately 120 million people worldwide each year and causes about 1.3 million deaths. Nearly 80% of pneumonia-related deaths among children occur in those under the age of two in developing countries. Therefore, the rising prevalence of pneumonia is contributing to the growth of the pneumonia therapeutics market.

Major companies operating in the pneumonia therapeutics market are focusing on the development of innovative drug formulations and treatment approaches, such as advanced antibiotic therapies, to address antibiotic resistance and improve patient outcomes. Antibiotic drugs are medications specifically designed to treat bacterial infections. For instance, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited, another India-based pharmaceutical company, to launch cefepime-enmetazobactam. This antibiotic combination is used to treat complex infections, including pneumonia and urinary tract infections, particularly those that are resistant to other treatments. The therapy helps counter bacterial resistance while reducing the need for more potent antibiotics.

In June 2023, Novo Holdings and Gurnet Point Capital, US-based investment firms, acquired Paratek Pharmaceuticals, Inc. for approximately US$462 million. Through this acquisition, the firms obtained Paratek’s antibiotic portfolio, including Nuzyra (omadacycline), an FDA-approved therapy for community-acquired bacterial pneumonia. This acquisition strengthened their position in the pneumonia therapeutics market. Paratek Pharmaceuticals, Inc. is a US-based biopharmaceutical company that develops antibiotic treatments, including Nuzyra, which is available in both oral and intravenous formulations for the treatment of bacterial pneumonia.

Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc.

North America was the largest region in the pneumonia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pneumonia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the pneumonia therapeutics market by increasing costs of imported active pharmaceutical ingredients, medical-grade gases, ventilatory equipment, and diagnostic supplies required for effective treatment. Hospitals and healthcare providers in North America and Europe are most impacted due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces higher production costs for export-oriented drug manufacturing. These tariffs are raising treatment costs and influencing procurement strategies. At the same time, they are encouraging localized drug manufacturing, regional API sourcing, and strengthened domestic pharmaceutical production capabilities.

The pneumonia therapeutics market research report is one of a series of new reports that provides pneumonia therapeutics market statistics, including pneumonia therapeutics industry global market size, regional shares, competitors with a pneumonia therapeutics market share, detailed pneumonia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. This pneumonia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pneumonia therapeutics encompass a range of treatments and medications used to manage and treat pneumonia, a lung infection caused by bacteria, viruses, or fungi. These therapies are designed to target the underlying pathogens, reduce inflammation, and improve respiratory function. Treatment options include antibiotics for bacterial pneumonia, antiviral drugs for viral pneumonia, and antifungal agents for fungal infections.

The primary products in pneumonia therapeutics include drugs, vaccines, and oxygen therapy. Therapeutic drugs address the underlying cause of infection and help relieve symptoms through the use of antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated include hospital acquired pneumonia, community acquired pneumonia, and ventilator associated pneumonia. Routes of administration include oral, parenteral, and other methods, and these treatments are utilized by end users such as hospitals, home care settings, specialty clinics, and other healthcare facilities.

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.